Integra LifeSciences Holdings Corporation
IART
$15.10
-$0.02-0.13%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 81.75% | -108.77% | 49.48% | -3,803.18% | -670.89% |
| Total Depreciation and Amortization | 3.34% | -14.01% | 7.12% | 27.01% | 21.66% |
| Total Amortization of Deferred Charges | -28.16% | -27.50% | -1.50% | 29.45% | -0.93% |
| Total Other Non-Cash Items | 4,701.71% | -278.16% | -137.41% | 2,174.42% | -98.88% |
| Change in Net Operating Assets | -24.21% | -28.04% | 616.12% | -2,022.39% | -5.58% |
| Cash from Operations | 187.08% | -76.71% | 81.93% | -77.92% | -171.45% |
| Capital Expenditure | 48.66% | 41.84% | 48.88% | 32.18% | -87.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -183.58% | -102.24% | 85.69% | 81.82% |
| Cash from Investing | 58.66% | -721.53% | -49.94% | 93.28% | 33.44% |
| Total Debt Issued | -18.20% | 40.40% | 2,669.27% | -78.06% | -85.32% |
| Total Debt Repaid | -133.46% | 37.19% | -1,377.16% | 82.45% | -0.95% |
| Issuance of Common Stock | -20.59% | -- | -- | -- | -85.04% |
| Repurchase of Common Stock | 35.63% | 94.74% | -16.37% | 99.11% | 31.58% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -48.50% | -- |
| Cash from Financing | -76.55% | 440.45% | 48.56% | 77.45% | -90.14% |
| Foreign Exchange rate Adjustments | -132.92% | 119.83% | -110.34% | 1,226.93% | 191.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 124.22% | -90.83% | 18,165.82% | 94.37% | -102.30% |